CTI BioPharma Corp.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CTI BioPharma Corp. - overview
Established
1991
Location
Seattle, WA, US
Primary Industry
Pharmaceuticals
About
CTI BioPharma Corp. is a biopharmaceutical company specializing in the development of innovative cancer therapies aimed at addressing significant unmet medical needs in oncology treatment. Founded in 1991 and headquartered in Seattle, US, CTI BioPharma Corp. focuses on developing proprietary therapies for cancer care.
The company has not undergone any business pivots or structural changes since its formation. CTI BioPharma Corp. advances innovative treatments in oncology, featuring flagship products that target various forms of cancer. Their proprietary technologies are developed to improve patient outcomes by enhancing treatment efficacy and minimizing side effects.
The primary clientele consists of healthcare institutions, including hospitals and oncology clinics, which utilize these therapies in their treatment protocols. The company has established a presence in North America and Europe to provide access to its advanced cancer treatments. In the most recent year, CTI BioPharma Corp. generated revenue of USD 53.
95 mn with an EBITDA of USD -77. 85 mn, primarily through business-to-business transactions with healthcare providers and oncology centers. CTI BioPharma Corp. is focused on launching new oncology products and expanding its market presence.
Specific geographic regions targeted for expansion include additional markets in Europe and Asia by 2025. The recent funding will support these initiatives by facilitating the development of new therapies and enhancing marketing efforts in these expanding regions.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.celltherapeutics.com
Total Amount Raised
Subscriber access only
CTI BioPharma Corp. - timeline of key events
CTI BioPharma Corp. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 34,678,000 | 60,077,000 | 16,116,000 | 57,405,000 | 25,146,000 | 26,290,000 | 3,345,000 | - | - | - |
| % Revenue Growth (YoY) | - | 73.2% | (73.2%) | 256.2% | (56.2%) | 4.5% | (87.3%) | - | - | - |
| EBITDA (USD) | (39,956,000) | (85,133,000) | (115,676,000) | (48,331,000) | (38,802,000) | (32,306,000) | (40,165,000) | - | - | - |
| Operating Income (USD) | (41,526,000) | (86,233,000) | (116,666,000) | (49,162,000) | (39,519,000) | (32,899,000) | (40,711,000) | - | - | - |
| Operating Margin | (119.7%) | (143.5%) | (723.9%) | (85.6%) | (157.2%) | (125.1%) | (1217.1%) | - | - | - |
| % EBITDA Margin | (115.2%) | (141.7%) | (717.8%) | (84.2%) | (154.3%) | (122.9%) | (1200.7%) | - | - | - |
| NET Income (USD) | (43,550,000) | (94,229,000) | (120,763,000) | (52,953,000) | (40,831,000) | (29,352,000) | (40,023,000) | - | - | - |
| % Net Margin | (125.6%) | (156.8%) | (749.3%) | (92.2%) | (162.4%) | (111.6%) | (1196.5%) | - | - | - |
CTI BioPharma Corp. - employee data
CTI BioPharma Corp. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| President, CSO and Board of Directors | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.